Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
University of Rochester Medical Center, Rochester, NY, USA.
Acta Neurol Scand. 2017 Dec;136(6):694-697. doi: 10.1111/ane.12788. Epub 2017 Jun 28.
Generic patient reported outcome measures have had varied success in tracking QoL in myotonic dystrophy type 1 (DM1).
To analyze changes of Individualized Neuromuscular Quality of Life questionnaire (INQoL) scores in clinic patients with DM1 over a 6-year period.
Patients completed the INQoL at baseline and after a 6-year period through their attendance in a neurology outpatient clinic. Severity of muscular involvement in DM1 was analyzed using the Muscular Impairment Rating Scale (MIRS).
Ninety-nine DM1 patients completed a baseline visit. Sixty-seven of these patients were retested at an interval time. The overall INQoL score improved in our sample of patients (P<.05) as did the following subscales: myotonia (P<.05), pain (P<.05), activities (P<.01), social relationships (P<.01), and body image (P<.05). No changes were observed for the independence and emotions scales. There were no differences in mean change of INQoL scores between patients with worsened MIRS and those with no change in MIRS scale after follow-up (P>.05).
Individualized Neuromuscular Quality of Life questionnaire scores improved in our cohort of DM1 patients during a 6-year period. INQoL score did not correlate with progression of muscle weakness. This must be better understood before the selection of the instrument for use in trials to measure therapeutic benefit in DM1 patients.
通用患者报告结局测量在追踪肌强直性营养不良 1 型(DM1)患者的生活质量方面取得了不同程度的成功。
分析 6 年内接受 DM1 神经内科门诊治疗的患者个体化神经肌肉生活质量问卷(INQoL)评分的变化。
患者在基线和 6 年后通过神经内科门诊就诊完成 INQoL 问卷。使用肌肉功能障碍评分量表(MIRS)分析 DM1 肌肉受累的严重程度。
99 例 DM1 患者完成了基线访视。其中 67 例患者在间隔时间内接受了重复测试。我们的患者样本总体 INQoL 评分有所改善(P<.05),以下子量表也有所改善:肌强直(P<.05)、疼痛(P<.05)、活动能力(P<.01)、社会关系(P<.01)和身体形象(P<.05)。独立性和情绪量表无变化。随访后 MIRS 评分无变化和 MIRS 评分恶化的患者 INQoL 评分平均变化无差异(P>.05)。
在 6 年期间,我们的 DM1 患者队列的个体化神经肌肉生活质量问卷评分有所提高。INQoL 评分与肌肉无力的进展无关。在选择用于测量 DM1 患者治疗获益的工具之前,必须更好地理解这一点。